Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on IBS-C (Oct 2020)

Posted by Matt Breese on Oct 9, 2020

Find me on:

According to our recent payer coverage analysis for the treatment of irritable bowel syndrome with constipation (IBS-C), combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for IBS-C treatments shows that under the pharmacy benefit, about 40% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-IBS-C-4Q2020Data snapshot as of Q3 2020

Trends: In September 2020, the FDA authorized an investigational new drug (IND) application from Seed Health to evaluate the impact of its DS-01, a broad spectrum probiotic, on gut microbiota of patients with irritable bowel syndrome.  

To read the full Reality Check on IBS-C treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing